Home > Neurology > MTIS 2020 > Contents > Sustained shift in migraine status using galcanezumab

Sustained shift in migraine status using galcanezumab

Presented By
Dr William S. Kingston, Sunnybrook Health Sciences Centre, Canada
Conference
MTIS 2020
Trial
Phase 3, CONQUER
Galcanezumab resulted in a significant shift from chronic to episodic migraine status as well as from high- to low-frequency episodic migraine in patients with treatment-resistant migraine [1]. These sustained shifts, as found in the CONQUER trial, suggest that galcanezumab may result in reduced rates of disability and consequent lowering of the disease burden associated with chronic and high-frequency episodic migraine. Due to higher disability, comorbidity, and healthcare resource utilisation, chronic migraine and high-frequency episodic migraine have a higher disease burden compared with low-frequency episodic migraine. CONQUER was a phase 3, multicentre, randomised controlled study in adult patients with treatment-resistant chronic or episodic migraine, who failed at 2-4 migraine-preventive medication categories over the past 10 years. The current ana...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on